Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksALM.L Regulatory News (ALM)

  • There is currently no data for ALM

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Allied Minds forms Seamless Devices, Inc.

30 Oct 2014 07:00

RNS Number : 6527V
Allied Minds PLC
30 October 2014
 



 

 

 

For immediate release

 

Media contact:

Christine Dunn

ArcPoint Strategic Communications

617.484.1660, x101

cdunn@arcpointstrategy.com

 

 

Allied Minds Announces the Formation of Seamless Devices, Inc.

 

· Seamless Devices is developing applications for an innovative analog signal processing technique that can produce high-performance signals even as transistor sizes scale down.

· The technology offers the potential for a broad range of applications across industries including: consumer electronics such as wearable sensors; embedded and connected devices; telecommunications; healthcare; and, transportation.

· Allied Minds licensed the technology from Columbia University in its first agreement with this U.S. Ivy League institution.

Boston (October 30, 2014) - Allied Minds (LSE: ALM), an innovative U.S. science and technology development and commercialization company, today announced that it's entering into an exclusive, worldwide licensing agreement with Columbia University that has led to the formation of a new subsidiary, Seamless Devices, Inc.

 

Seamless Devices is developing applications for a novel technique in analog signal processing that will make it possible to produce high-performance signals even as transistors are scaled down in size deep into the nanoscale.

 

The technology, developed in the laboratory of Columbia University Electrical Engineering Professor Peter Kinget, serves a wide range of applications across several industries, including consumer electronics, telecommunications hardware, instrumentation, network hardware, healthcare devices, transportation and military systems.

 

"We are excited by the opportunity to work with Columbia University on the commercialization of this new technology," said Chris Silva, Chief Executive Officer of Allied Minds. "Analog signals - music, speech, images, biomedical signals and radio waves, to name a few - are ubiquitous and touch every aspect of our daily lives. This new processing technique will enable the development of innovative devices with higher performance, lower power consumption, and smaller sizes."

 

Initially, Seamless Devices will be working on solutions for the semiconductor intellectual property (IP) market, which involves developing and licensing circuit designs that are incorporated into system-on-chip integrated circuits. Within this analog IP market, the company expects to be able to offer analog-to-digital converters (ADC) for telecom applications, as there is accelerating demand for ADCs that can operate at high bandwidth and high resolution with low power consumption.

 

"The markets, both industrial and consumer-facing, are pushing for ever smarter, more connected, embedded devices with smaller footprints," said Orin Herskowitz, Executive Director of Columbia Technology Ventures, the technology transfer office of Columbia University. "Dr. Kinget and his team have developed an elegant and timely approach that plays directly into the insatiable demand for ubiquitous electronics. We are delighted to be partnering with Allied Minds to bring this exciting technology to market."

 

As circuit chips become smaller in size, the voltages available to circuit elements become lower, presenting difficulties for analog and mixed-signal processing. Seamless Devices' switched-mode analog signal processing technology takes advantage of the fact that the timing resolution in integrated circuits is becoming more accurate, transforming analog signals into a time-based form that preserves a high degree of signal fidelity. 

 

Seamless Devices is a subsidiary of Boston-based Allied Minds. More information about the company and its research can be found at www.alliedminds.com/subsidiaries/seamless.

 

About Allied Minds

Allied Minds (LSE: ALM) is an innovative U.S. science and technology development and commercialization company. Operating since 2006, Allied Minds forms, funds, manages and builds products and businesses based on innovative technologies developed at leading U.S. universities and federal research institutions. Allied Minds serves as a diversified holding company that supports its businesses and product development with capital, central management and shared services. More information about the Boston-based company can be found at www.alliedminds.com.

 

About Columbia University

A leading academic and research university, Columbia University continually seeks to advance the frontiers of knowledge and to foster a campus community deeply engaged in understanding and addressing the complex global issues of our time. Columbia University's technology transfer office, Columbia Technology Ventures, manages Columbia's intellectual property portfolio and serves as the university's gateway for companies and entrepreneurs seeking novel technology solutions. Our core mission is to facilitate the transfer of inventions from academic research to outside organizations for the benefit of society on a local, national and global basis. For more information on Columbia Technology Ventures, please visit www.techventures.columbia.edu.

Allied Minds Forward-Looking Statement

This press release contains statements that are or may be forward-looking statements, including statements that relate to the company's future prospects, developments and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks and uncertainties that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risk and uncertainties described in the risk factors included in the company's regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law, regulatory requirement, the Prospectus Rules, the Listing Rules and the Disclosure and Transparency Rules, neither the company nor any other party intends to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCFEFFAUFLSESS
Date   Source Headline
16th Jul 20217:00 amRNSTransaction in Own Shares
13th Jul 20217:00 amRNSTransaction in Own Shares
7th Jul 20217:00 amRNSTransaction in Own Shares
5th Jul 20217:00 amRNSTransaction in Own Shares
2nd Jul 20217:00 amRNSTransaction in Own Shares
1st Jul 20217:00 amRNSTransaction in Own Shares
30th Jun 20217:00 amRNSTransaction in Own Shares
29th Jun 20217:00 amRNSTransaction in Own Shares
28th Jun 20217:00 amRNSTransaction in own shares
25th Jun 20217:00 amRNSTransaction in own shares
24th Jun 20217:00 amRNSTransaction in own shares
23rd Jun 20217:00 amRNSPortfolio company update and share buyback
16th Jun 20214:41 pmRNSSecond Price Monitoring Extn
16th Jun 20214:36 pmRNSPrice Monitoring Extension
3rd Jun 20214:41 pmRNSSecond Price Monitoring Extn
3rd Jun 20214:35 pmRNSPrice Monitoring Extension
1st Jun 20217:00 amRNSOcuTerra Therapeutics Series B Second Close
24th May 20214:41 pmRNSSecond Price Monitoring Extn
24th May 20214:36 pmRNSPrice Monitoring Extension
18th May 20214:40 pmRNSSecond Price Monitoring Extn
18th May 20214:35 pmRNSPrice Monitoring Extension
12th May 20215:28 pmRNSResult of AGM
11th May 20217:00 amRNSBlock listing Interim Review
11th May 20217:00 amRNSBlock listing Interim Review
11th May 20217:00 amRNSBlock listing Interim Review
28th Apr 20217:00 amRNSOcuTerra Therapeutics Raises Series B Financing
15th Apr 20217:00 amRNSBlock Listing Application
13th Apr 20217:00 amRNSOrbital Sidekick Closes $16m Series A Financing
9th Apr 20217:00 amRNSCapital Markets Day
6th Apr 20217:00 amRNSNotice of AGM
1st Apr 20215:34 pmRNSHolding(s) in Company
30th Mar 20217:00 amRNSAnnual results release
29th Mar 20214:28 pmRNSHolding(s) in Company
22nd Mar 20217:00 amRNSNotice of results - update
18th Mar 20214:41 pmRNSSecond Price Monitoring Extn
18th Mar 20214:36 pmRNSPrice Monitoring Extension
11th Mar 20214:36 pmRNSPrice Monitoring Extension
1st Mar 20219:00 amRNSNotice of Results
23rd Feb 20217:00 amRNSBridgeComm Advances Development of MOCA Technology
2nd Feb 20219:33 amRNSDirector/PDMR Shareholding
22nd Jan 20214:36 pmRNSPrice Monitoring Extension
15th Jan 20217:00 amRNSDirectorate Change
8th Jan 20214:36 pmRNSPrice Monitoring Extension
4th Jan 20215:15 pmRNSHolding(s) in Company
4th Jan 20217:00 amRNSStrategic update
24th Dec 20207:00 amRNSOrbital Sidekick Series A Financing
21st Dec 20203:25 pmRNSFederated Wireless partners with TESSCO
1st Dec 20203:35 pmRNSTotal Voting Rights
23rd Nov 20204:36 pmRNSPrice Monitoring Extension
19th Nov 20207:00 amRNSShareholder engagement update on 2020 AGM vote

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.